An Early Phase 1 interventional study of Hydromorphone Hydrochloride Extended-Release Tablets and Electroacupuncture in Refractory Cancer Pain and Cancer Pain, sponsored by Qinghai Red Cross Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-14.
Sponsored by Qinghai Red Cross Hospital · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Cancer Pain with a site in China — 13 open to participants now, 13 under way, 1 of them phase 3. Cancer Pain · China.
Among the 31 studies in Cancer Pain with a site in China, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 1, reaches primary completion later than 8 of the 12 other live ones, and was the 27th registered.
311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.
Browse Cancer Pain studies →13 of the 31 studies in Cancer Pain with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–75
Taian Cancer Hospital · Sites in China
Ages 65+
Tongji Hospital · Sites in China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
The Third Affiliated hospital of Zhejiang Chinese Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 1
First in 2012; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 63 across 236 interventional studies indexed under Cancer Pain.
Median enrollment 110 across the 24 interventional studies, 200 across the 7 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 31 have an industry lead sponsor. The 10 most frequent:
Qinghai Red Cross Hospital is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Qinghai Red Cross Hospital has 1 study filed under Cancer Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Cancer Pain with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07657390Cancer Institute and Hospital, Chinese Academy of Medical SciencesProspective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain | 2026-12-31 |
| NCT07869797Mundipharma (China) Pharmaceutical Co. LtdReal-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Cancer Pain with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial aims to address refractory cancer pain (RCP). It will explore the synergistic efficacy and safety of hydromorphone hydrochloride sustained-release tablets (HHST) combined with electroacupuncture (EA) and ear acupoint pressing beans (EAPB) for RCP. Key outcomes will include dynamic changes in Numerical Rating Scale (NRS) scores, proportions of patients with effective analgesia (≥30% NRS reduction from baseline) and marked remission (≥50% NRS reduction from baseline), daily HHST dosage, breakthrough pain (BP) frequency, and drug-related adverse events (AEs) graded by CTCAE 6.0.
This study is a prospective, single-arm clinical trial designed to address the therapeutic challenge of refractory cancer pain (RCP). It will systematically explore the synergistic therapeutic effect of hydromorphone hydrochloride sustained-release tablets (HHST) combined with electroacupuncture (EA) and ear acupoint pressing beans (EAPB). Through a clinical research design, the study will comprehensively evaluate the efficacy and safety of this combined regimen in relieving RCP.
The primary observational focus of the study will be the dynamic changes in the Numerical Rating Scale (NRS) scores of patients before and after treatment. Researchers will quantitatively analyze the proportion of patients achieving effective analgesia (defined as a ≥30% reduction in NRS score from baseline) and marked remission (defined as a ≥50% reduction in NRS score from baseline). Meanwhile, the study will monitor key indicators to verify the analgesic efficacy and safety of the combined regimen from multiple dimensions: the daily dosage of HHST, the frequency of breakthrough pain (BP) episodes, and drug-related adverse events (AEs). All AEs will be graded in accordance with the Common Terminology Criteria for Adverse Events, Version 6.0 (CTCAE 6.0).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Hydromorphone Hydrochloride Extended-Release Tablets · Procedure: Electroacupuncture · Procedure: Ear Acupoint Pressing Beans
Extended-release hydromorphone hydrochloride tablets will be initiated at a dose converted from the total 24-hour opioid dose before treatment, rounded down to the nearest whole tablet, and administered orally once daily.Patients will be evaluated every 24 hours, and the dosage will be adjusted according to changes in pain intensity and Numerical Rating Scale (NRS) score.The dose will be maintained if the daily baseline pain NRS score is ≤3 and breakthrough pain occurs ≤2 times per day.If the daily baseline pain NRS score is \>3 or breakthrough pain occurs \>2 times per day, the dose may be titrated upward or downward based on adverse reactions. The dose will be titrated upward with an increment of 8 mg, and the interval between dose titrations shall be at least 2 days.
Electroacupuncture will be performed at three specific points: Zusanli (ST36), Quchi (LI11), and Kunlun (BL60). Following needle insertion and deqi sensation, electrodes will be connected to an electroacupuncture device delivering 2Hz dense-disperse wave stimulation for 30 minutes. One treatment cycle lasts 7 days, and treatment will be administered once daily for a total of 14 days.
Six auricular acupoints will be selected, including Shenmen, Subcortex, Sympathetic, Endocrine, Liver, and Kidney. Vaccaria seeds will be attached to these acupoints and gently pressed with fingers until the patient experiences a sensation of soreness and distension. For continuous stimulation, pressing will be performed 3-5 times daily, 1-2 minutes each time, for a duration of 3-5 days.
Comparison of changes in Numerical Rating Scale (NRS) pain score between baseline and post-treatment.
Pain intensity will be measured by the Numerical Rating Scale (0-10).Primary endpoints:(1) Analgesic efficacy rate: proportion of patients with ≥30% reduction in NRS from baseline;(2) Significant relief rate: proportion with ≥50% reduction in NRS from baseline.Assessments will be conducted at baseline and at the end of the 2-week treatment.
Time frame: 2 weeks
Comparison of the change in dosage of hydromorphone hydrochloride extended-release tablets during treatment.
The initial dose will be the equivalent dose of hydromorphone hydrochloride sustained-release tablets converted from the total opioid dose administered in the previous 24 hours. The dose will be titrated upward or downward according to daily baseline pain intensity, frequency of breakthrough pain, and occurrence of adverse reactions.
Time frame: 2 weeks
Comparison of the daily frequency of breakthrough pain between baseline and post-treatment.
Breakthrough cancer pain (BTcP) is defined as a transient exacerbation of pain that occurs suddenly while baseline cancer pain is relatively well controlled, either spontaneously or induced by specific triggers.The daily frequency of breakthrough cancer pain (BTcP) episodes will be observed in patients during the treatment period.
Time frame: 2 weeks
Adverse Drug Reactions
This study will evaluate the incidence and severity of adverse reactions associated with hydromorphone hydrochloride sustained-release tablets during the treatment period.Adverse events will be graded in accordance with the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE 5.0).
Time frame: 2 weeks
Comparison of changes in health-related quality of life from baseline to post-treatment.
Assessment using the European Quality of Life 5-Dimensions (EQ-5D) questionnaire.The EQ-5D is a standardized health-related quality of life instrument consisting of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.Each dimension has 3 response levels to describe the patient's functional status or health state.In addition, the EQ-5D includes a visual analogue scale (EQ-VAS) where patients rate their overall health status on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: 2 weeks
Incidence of Adverse Reactions Associated with Electroacupuncture and Ear Acupoint Pressing Beans
This study will evaluate the incidence, severity of adverse reactions related to electroacupuncture and auricular point pressing therapy, as well as treatment compliance during the treatment period. Adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Time frame: 2 weeks
Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydromorphone
Qinghai Red Cross Hospital